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We examined whether hemorheology and platelet function are aﬀected in essential hypertensives (EHTs) of the World Health
Organization stage I when complicated with metabolic syndrome (Mets). In 156 untreated EHTs, blood viscosity and platelet
surface markers were determined. Blood viscosity was signiﬁcantly elevated in 54 subjects with Mets compared with 102 subjects
withoutMets.HematocritandplasmaviscosityincreasedinthegroupwithMets,althoughredbloodcellrigidityindex“k”didnot
diﬀer between groups. As a whole group, blood viscosity correlated positively with hematocrit and plasma viscosity. Additionally,
plasma viscosity correlated positively with plasma leptin, triglyceride, homeostasis model assessment index, C-reactive protein,
and plasma ﬁbrinogen, but negatively with high-density lipoprotein cholesterol. In contrast, no diﬀerences were seen in platelet
surfacemarkersbetweengroups.Inconclusion,EHTsoftheearlystagecomplicatedwithMetsarecharacterizedbyincreasedblood
viscosity due to hemoconcentration and increased plasma viscosity.
1.Introduction
Blood viscosity is one of the known determinants of vascular
resistance and shear stress in the cardiovascular system, as
shown by the Poiseuille equation [1]. Activation of platelets
results in platelet aggregation and release of adenosine
diphosphate(ADP),5-hydroxytryptamine,thromboxaneA2,
and platelet-derived growth factor, thereby contributing
to thrombus formation, vascular structural changes, and
atherosclerosis [2–4]. Accordingly, increase in blood viscos-
ity, platelet activation, or both is presumed to play a part in
the pathogenesis of hypertension and other cardiovascular
diseases.
In 1999, metabolic syndrome (Mets) was ﬁrst deﬁned
as a cluster of cardiovascular risk factors including obesity,
impaired glucose tolerance, elevated blood pressure, and
abnormalities of lipid metabolism [5]. Recently, epidemio-
logic studies have shown that patients with Mets have higher
cardiovascular mortality and morbidity than the general
population[6,7].Theincreasedprevalenceofcardiovascular
diseases in Mets may be explained in part by abnormalities
of blood viscosity or platelet function. In fact, increased
blood viscosity and increased platelet reactivity are often
found in patients with Mets [8–11]. Furthermore, it is well
known that patients with essential hypertension also have
increased blood viscosity [12, 13] and activated platelets
[2,14]andareoftencomplicatedwithMets[15].However,it
has not yet been elucidated how blood rheology and platelet
functions are modulated in essential hypertensives (EHT)
classiﬁedasstageIoftheWorldHealthOrganization(WHO)
severity score of hypertension [16] when complicated with
Mets. In the present study, therefore, blood viscosity, platelet
function, and factors possibly aﬀecting these two indices
were compared between early-stage EHT complicated with
and without Mets.
2. Methods
2.1. Subjects. The study design was approved by the Ethics
Committee at the University of Toyama. Untreated 156 EHTs2 International Journal of Hypertension
(90 men, age 55 ±12 years) were consecutively enrolled into
the study after obtaining informed consent. The diagnosis
of hypertension was made on the basis of a sitting diastolic
blood pressure measured with a sphygmomanometer more
than 90mmHg and/or systolic blood pressure more than
140mmHgonthreeseparateoccasionsovera4-weekperiod.
All subjects met the criteria for stage I on the WHO severity
score of hypertension [16]. Of 66 female patients, 46 (70%)
were postmenopausal, and none were on hormone replace-
ment therapy. We excluded patients having macroalbumin-
uria (i.e., urinary albumin >300mg/day), impaired renal
function (i.e., creatinine clearance <60mL/min/1.73m2),
secondary hypertension, diabetes mellitus, clinically evident
cardiovascular diseases, or anemia. All medications that
might aﬀect blood viscosity or platelet function, for exam-
ple, antiplatelet agents and nonsteroidal anti-inﬂammatory
drugs, were discontinued at least 4 weeks prior to study
commencement.
2.2. Study Protocol. Mets was diagnosed following the Japa-
nese diagnostic criteria [17] if patients had visceral obesity
deﬁned as waist circumference 8 5a n d9 0c mi nm e na n d
women, respectively, and at least one of the following risk
factors:(1)fastingbloodglucose110mg/dLand(2)plasma
triglyceride 150mg/dL and/or high density lipoprotein
(HDL) cholesterol <40mg/dL. Because various diagnostic
criteriaforMetsexist,IDFdeﬁnition[18],oneoftheinterna-
tional criteria for Mets, was also employed.
Blood viscosity and platelet function were determined at
theoutpatientclinicinthemorning.Patientswereinstructed
not to take food, alcohol, caﬀeine, or cigarettes within the
12-hour period before the measurements. A venous catheter
was inserted into the antecubital vein, and following 30min
supine rest, venous blood was collected gently without
vein occlusion. Blood samples for determination of blood
viscosity and platelet function were collected in tubes con-
taining potassium EDTA and 0.38% sodium citrate, respec-
tively, as anticoagulants. Blood samples were also taken for
determination of parameters aﬀecting hemorheology and
platelet function [14, 19–22]. These included (1) hematocrit,
(2) biochemical indices of glucose and lipid metabolism, (3)
high-sensitive C-reactive protein (HS-CRP) as a marker of
inﬂammation,and(4)plasmalevelsofleptinandﬁbrinogen.
Subsequently, 24-hour urine collections were obtained for
measurement of creatinine clearance and urinary albumin
excretion.
For the hemorheological measurements, whole blood
viscosity and plasma viscosity were determined using a
falling ball microviscometer (AMVn-200, Anton Paar, Aus-
tria). This instrument comprises a glass capillary tube of
0.16mm internal diameter containing a metallic ball of
0.15mmdiameter.Fluidviscosityisdeterminedbythefalling
time of the ball in the tube inclined at 70 degrees ﬁlled
with blood or plasma at 20◦C[ 23, 24]. In this setting, ﬂuid
viscosity is measured at a high shear rate between 2500 and
3000s−1, which allows measurement of blood viscosity in a
completely disaggregated structure. In such a situation, it is
theoretically considered that blood viscosity depends mainly
on three parameters including plasma viscosity, red blood
cell (RBC) rigidity, and hematocrit [24]. RBC rigidity was
also evaluated using the RBC rigidity index “k” calculated
according to the Quemada equation [25].
For determination of platelet functions, platelet surface
markers were analyzed using whole-blood ﬂow cytome-
try (EPICS XL, Coulter, Miami, FL, USA) [26]. A 5μL
sample of citrated blood was diluted in 50μLo f1 0 m M
HEPES buﬀer and mixed with vehicle or 1.0μM ADP as
a platelet agonist. Then, 5μL of ﬂuorescein isothiocyanate-
conjugated anti-ﬁbrinogen polyclonal antibody (Beckman
Coulter,Inc.,Miami,FL,USA),orphycoerythrin-conjugated
anti-P-selectin monoclonal antibody (Beckman Coulter,
Inc., Miami, FL, USA) was added, and the ratios of platelet
ﬁbrinogen binding and P-selectin expression were counted
in 5000 platelets. In 9 healthy volunteers (5 men and 4
women), reproducibility of blood viscosity, plasma viscosity,
and platelet surface markers was determined on 4 occasions
at 1 week intervals. The intra subject coeﬃcient of variance
for these measurements was less than 5%.
Biochemical parameters were measured using conven-
tional laboratory techniques. Insulin resistance was esti-
mated according to the homeostasis model assessment
(HOMA) as follows: HOMA index of insulin resistance
(HOMA-IR) = fasting glucose (mg/dL) × fasting plasma
insulin (μIU/mL)/405. Plasma leptin levels were determined
using commercial ELISA kits (Cayman Chemical, Ann
Arbor, MI, USA).
2.3. Data Analyses. Data are presented as mean ± standard
deviation (SD). Comparisons were made between EHT with
and without Mets using Student’s t-test or chi-square (χ2)
test. In all patients, associations of blood viscosity or plasma
viscosity with the factors possibly aﬀecting these two indices
were evaluated using Pearson’s correlation. A P value less
than 0.05 was considered statistically signiﬁcant.
3. Results
Metswaspresentin54patientsbasedontheJapanesecriteria
and in 55 based on the IDF criteria. Clinical characteristics,
hemorheological indices, and platelet functions were similar
between the two groups of patients with Mets (data not
shown); therefore, the data analyses using the Japanese
criteria of Mets are presented herein.
3.1. Clinical Characteristics. Due to the study design, body
mass index and waist circumference were greater in patients
with Mets than in those without Mets (Table 1). The
proportion of patients with impaired glucose tolerance or
dyslipidemia was also greater in patients with Mets than in
those without Mets. No signiﬁcant diﬀerences were seen in
age, gender, prevalence of familial clustering of hypertension
and menopause, and proportion of smokers between the
two groups. Blood pressure at the outpatient clinic tended
to be higher in patients with Mets than in those without
Mets, although the diﬀerence was not statistically signiﬁcant
(Table 1).International Journal of Hypertension 3
Table 1: Comparison of clinical characteristics between essential
hypertensives with and without metabolic syndrome.
Variables
Metabolic syndrome
P value
(−)( + )
Number 102 54
Age (years) 55 ±12 55 ±12 0.935
Sex (men/women) 56/46 34/20 0.332
Menopause in female
patients 30 (65) 16 (80) 0.229
Body mass index
(kg/m2) 23.5 ±3.72 7 .7 ±2.9 <0.001
Waist circumference
(cm) 81 ±88 9 ±11 <0.001
Family history of
hypertension 64 (63) 34 (63) 0.979
Current smoker 13 (13) 11 (20) 0.209
Impaired glucose
tolerance 3 (3) 29 (54) <0.001
Dyslipidemia 5 (5) 30 (56) <0.001
Systolic blood pressure
(mmHg) 153 ±20 160 ±21 0.051
Diastolic blood pressure
(mmHg) 93 ±14 97 ±15 0.101
Pulse rate
(beats/minutes) 72 ±13 70 ±10 0.311
Values are mean ± SD or number (%) of patients. Impaired glucose toler-
ance was deﬁned as fasting blood glucose ≥ 110mg/dL, and dyslipidemia as
plasma triglyceride ≥ 1 5 0m g / d La n d / o rH D Lc h o l e s t e r o l<40mg/dL.
3.2. Hemorheological Measurements and Platelet Functions
(Table 2). Bloodviscositywassigniﬁcantlyhigherinpatients
with Mets than in those without Mets. Both plasma viscosity
and hematocrit were higher in patients with Mets compared
with those without Mets, although RBC rigidity index “k”
did not diﬀer between groups. In contrast, no diﬀerence was
seen in platelet function, estimated by ﬁbrinogen binding
and P-selectin expression, between groups.
3.3. Biochemical Variables (Table 3). Due to the study design,
serum levels of triglyceride, HOMA-IR, and HS-CRP were
higher in patients with Mets than in those without Mets.
By contrast, HDL-cholesterol levels were signiﬁcantly lower
in patients with Mets. Plasma leptin levels were higher in
EHT with Mets compared with those without Mets, but no
diﬀe r e n c ew a ss e e ni np l a s m aﬁ b r i n o g e nb e t w e e ng r o u p s .
3.4. Factors Associated with Blood Viscosity or Plasma Viscos-
ity. Inthegroupofallthepatients,bloodviscositycorrelated
signiﬁcantly to body mass index (r = 0.301, P<0.001)
and waist circumference (r = 0.230, P = 0.004), although
it did not correlate to systolic blood pressure, diastolic blood
pressure, or pulse rate (r =− 0.031, 0.048, or 0.025 for each,
ns). In addition, blood viscosity correlated positively with
hematocrit (r = 0.757, P<0.001) and also with plasma
viscosity (r = 0.303, P<0.001). Plasma viscosity correlated
positively with HS-CRP, plasma leptin, serum triglyceride,
Table 2: Comparison of hemorheological variables, red blood cell
(RBC) rigidity index “k”, hematocrit and platelet function between
essential hypertensives with and without metabolic syndrome.
Variables
Metabolic syndrome
P value
(−)( + )
Blood viscosity (mPa·S) 4.01 ±0.42 4.33 ±0.52 <0.001
Plasma viscosity (mPa·S) 1.73 ±0.07 1.76 ±0.07 0.019
RBC rigidity index “k”1 .73 ±0.11 1.76 ±0.13 0.237
Hematocrit (%) 39.4 ±3.64 0 .8 ±3.6 0.025
Fibrinogen binding
Vehicle (%) 24.2 ±8.12 6 .1 ±6.6 0.135
ADP 1.0μM( % ) 6 1 .5 ±19.16 4 .2 ±18.5 0.389
P-selectin expression
vehicle (%) 15.3 ±6.41 4 .7 ±4.8 0.567
ADP 1.0μM( % ) 4 8 .4 ±17.84 9 .0 ±16.9 0.848
Values are mean ± SD. ADP: adenosine diphosphate.
Table 3: Comparison of biochemical variables between essential
hypertensives with and without metabolic syndrome.
Variables
Metabolic syndrome
P value
(−)( + )
Total cholesterol (mg/dL) 191 ±35 207 ±50 0.025
Triglyceride (mg/dL) 84 ±43 148 ±75 <0.001
HDL-cholesterol (mg/dL) 58 ±14 46 ±11 <0.001
Blood glucose (mg/dL) 94 ±9 102 ±11 <0.001
HOMA-IR 1.0 ±0.62 .3 ±2.4 <0.001
High-sensitive C-reactive
protein (mg/dL) 0.07 ±0.12 0.17 ±0.30 0.003
Plasma ﬁbrinogen (mg/dL) 236 ±49 242 ±57 0.513
Plasma leptin (μg/mL) 6.1 ±5.28 .6 ±5.9 0.008
Values are mean ± SD. HDL: high-density lipoprotein; HOMA-IR: home-
ostasis model assessment index of insulin resistance.
HOMA-IR, and plasma ﬁbrinogen, but negatively with
serum HDL-cholesterol level (Table 4).
4. Discussion
The major ﬁndings of the present study are as follows.
Firstly, whole blood viscosity was higher in EHT with Mets
than in those without Mets. Likewise, blood viscosity was
correlated with indices reﬂecting visceral fat mass such as
waist circumference, but not with systemic hemodynamics
in EHT. Secondly, no diﬀerence was seen in platelet function
between the two groups. Therefore, in the early-stage EHT
complicatedwithMets,thehemorheologicalproﬁleisaltered
as reported previously [9, 10], but platelet function is
unaltered.
Blood viscosity measured by microviscometer depends
mainly on plasma viscosity, RBC rigidity, and hematocrit
[25]. Plasma viscosity is also aﬀected by dyslipidemia,
insulin resistance, inﬂammation, and ﬁbrinogen [8, 19–
21]. Additionally, abnormal secretions of adipocytokines
can enhance cytokine productions and inﬂammation [22],4 International Journal of Hypertension
Table 4: Correlations between plasma viscosity and biochemical
variables.
Variables rP value
Triglyceride 0.236 0.003
HDL-cholesterol −0.204 0.011
Blood glucose 0.072 0.374
HOMA-IR 0.219 0.006
High-sensitive C-reactive protein 0.318 <0.001
Plasma ﬁbrinogen 0.382 <0.001
Plasma leptin 0.263 <0.001
Abbreviations are as in Table 3.
possibly resulting in increased plasma viscosity in patients
with Mets. In this study, elevated hematocrit and plasma
viscosity were observed in EHT with Mets compared with
those without Mets, although no diﬀerence was seen in
RBC rigidity. As a whole group, blood viscosity correlated
positively with hematocrit and plasma viscosity. As for the
above-mentioned factors possibly aﬀecting plasma viscosity,
increased levels of plasma leptin, triglyceride, HOMA-IR,
and serum HS-CRP and decreased level of HDL-cholesterol
were detected in EHT with Mets. Moreover, plasma viscosity
correlated positively with plasma leptin, serum triglyceride,
HOMA-IR, HS-CRP, and plasma ﬁbrinogen, but negatively
with serum HDL-cholesterol. From these results, the early-
stage EHTs with Mets are characterized by increased blood
viscosity due to hemoconcentration and increased plasma
viscosity. Furthermore, increased plasma viscosity can be
attributed to the alterations in serum leptin, glucose, and
lipid metabolism, inﬂammation, or plasma ﬁbrinogen, all of
which are often encountered in Mets.
Mets is characterized by disturbed secretion of adipocy-
tokines from visceral fat deposits, for instance, increased
secretion of leptin and decreased secretion of adiponectin.
Increased secretion of leptin can stimulate sympathetic
nervous system centrally [27]. On the other hand, decreased
secretion of adiponectin can induce insulin resistance, and
the subsequent hyperinsulinemia can enhance sympathetic
nervous activity. Therefore, these combined eﬀects can lead
to peripheral vasoconstriction, thereby moving intravascular
ﬂuidtotheinterstitialspace[28].Indeed,theabovesequence
ofeventsmayhaveledtohemoconcentrationinpatientswith
Mets in this study, as evidenced by levels of plasma leptin,
HOMA-IR, and hematocrit.
In contrast to blood viscosity, no diﬀerence was seen
in platelet function between the early-stage EHTs with
Mets and without Mets in the present study. Our previous
study demonstrated that platelet function was inﬂuenced
by sampling conditions (resting versus stress) and severity
of hypertension (WHO classiﬁcation) in EHT [2]. In the
present study, the measurements were performed at rest only
in EHT of the WHO stage I. Accordingly, further studies
are required under diﬀerent conditions and in EHT of more
advanced stages of hypertension to determine inﬂuences of
Mets on platelet function more clearly. The present study,
however, demonstrated that platelet function is not aﬀected
by Mets in EHT without cardiovascular complications.
4.1. Study Limitations. The present study has several lim-
itations. Firstly, this study was a cross-sectional study.
Therefore, further longitudinal studies will be required to
explore the long-term inﬂuences of abnormal hemorheolog-
icalpropertiesonsystemicbloodpressureandcardiovascular
complications in EHT with Mets. Secondly, the present study
did not include normotensive subjects with and without
Mets. These two groups should have been included to
draw a deﬁnite conclusion concerning the additive eﬀects
of hypertension and Mets on blood rheology and platelet
function. Thirdly, the eﬀects of therapeutic interventions on
abnormalitiesinbloodhemorheologyinEHTwithMetsalso
need to be studied. Alpha-1 blockers or calcium antagonists
could be recommended because they reduce blood viscosity
in EHT [29–31]. Finally, EHT of more advanced stages
should be studied, as the subjects in this study were conﬁned
to those without cardiovascular complications.
Although limited for these reasons, the present study
showed that presence of Mets is associated with an increase
in blood viscosity, without aﬀecting platelet function in EHT
of the WHO stage I. These results suggest that therapeutic
interventions againsthemorheologicalabnormalitiesneed to
be started earlier in order to prevent cardiovascular compli-
cations in EHT with Mets.
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